Serine/threonine kinase inhibitors

Patent metadata

Field	Value
Publication number	US-9867833-B2
Application number	US-201414559786-A
Country	US
Kind code	B2
Filing date	Dec 3, 2014
Priority date	Dec 6, 2013
Publication date	Jan 16, 2018
Grant date	Jan 16, 2018

Abstract

Compounds having the formula I wherein R 1 , X 1 , X 2 , X 3 and X 4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

First claim

We claim:

1. A compound of formula I wherein:

X 1 is N or CH;
X 2 is O;
X 3 is (CR 4 2 ) 2;
X 4 is CR 2 R 3 ;
R 1 is (i) a 4 to 7 membered saturated or partially unsaturated heterocyclyl or, (ii) a optionally substituted 5 to 6 membered heteroaryl;
R 2 is selected from the group consisting of:
(a) C 1-10 alkyl,
(b) C 2-10 alkenyl,
(c) C 1-10 haloalkyl,
(d) C 3-7 cycloalkyl or C 3-7 cycloalkyl-C 1-6 alkyl,
(e) C 3-7 halocycloalkyl or C 3-7 halocycloalkyl-C 1-6 alkyl,
(f) C 1-10 hydroxyalkyl or C 1-10 dihydroxyalkyl,
(g) C 1-3 alkoxy-C 1-6 alkyl,
(h) C 1-3 alkylthio-C 1-6 alkyl,
(i) C 1-10 cyanoalkyl,
(j) phenyl, phenyl-C 1-3 alkyl, phenoxy or benzyloxy-C 1-3 alkyl,
(k) heteroaryl, heteroaryl-C 1-3 alkyl or heteroaryloxy wherein said heteroaryl moiety is selected from the group consisting of pyrazolyl, imidiazolyl, oxazolyl, isoazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrid-2(1H)-one and 1-alkylpyrid-2(1H)-one and each said heteroaryl is independently optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, oxide, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano, C 3-6 cycloalkyl and C 1-6 alkyl wherein said C 1-6 alkyl is optionally independently substituted with one or more groups independently selected from halogen, oxo, hydroxyl or C 1-6 alkoxy; and,
(l) phenylthio or phenylthio-C 1-6 alkyl;

R 3 is hydrogen or C 1-3 alkyl;
R 4 is hydrogen;
R a and R b are independently hydrogen or C 1-3 alkyl; or,
a pharmaceutically acceptable salt thereof;
wherein any phenyl moiety is optionally substituted one or more halogen, cyano, hydroxyl, C 1-6 alkoxy, C 1-6 haloalkoxy or C 1-6 alkyl wherein said C 1-6 alkyl is optionally independently substituted with one or more groups independently selected from halogen, oxo, hydroxyl or C 1 - 6 alkoxy; and,
wherein each cycloalkyl is independently optionally substituted with one to three groups halogen, C 1-6 haloalkyl,C 1-6 alkoxy or C 1-6 haloalkoxy.

2. The compound according to claim 1 selected from:

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

4. A method of treating or ameliorating the severity of a hyperproliferative disorder in a patient in need thereof comprising administering to said patient a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein said hyperproliferative disorder is selected from the group consisting of adenoma, bladder cancer, brain cancer, breast cancer, colon cancer, epidermal carcinoma, follicular carcinoma, cancer of the genitourinary tract, glioblastoma, Hodgkin's disease, head and neck cancers, hepatoma, keratoacanthoma, kidney cancer, large cell carcinoma, leukemias, lung adenocarcinoma, lung cancer, lymphoid disorders, melanoma and non-melanoma skin cancer, myelodysplastic syndrome, neuroblastoma, non-Hodgkins lymphoma, ovarian cancer, papillary carcinoma, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, small cell carcinoma, testicular cancer, tetracarcinomas, thyroid cancer, and undifferentiated carcinoma.

5. The method according to claim 4 wherein said hyperproliferative disorder is selected from the group consisting of melanoma, pancreatic cancer, thyroid cancer, colorectal cancer, lung cancer, breast cancer and ovarian cancer.

6. The method according to claim 4 wherein said hyperproliferative disorder is selected from the group consisting of acute myelogenous leukemia, chronic myelomonocytic leukemia, chronic myelogenous leukemia, multiple myeloma and myeloid leukemia.

7. The method according to claim 4 wherein the compound, or pharmaceutically acceptable salt thereof, is co-administered with at least one other chemotherapeutic agent used to treat or ameliorate a hyperproliferative disorder; wherein the chemotherapeutic agent is selected from the group consisting of erlotinib, bortezomib, fulvestrant, sunitinib, letrozole, imatinib mesylate, vatalanib, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, bullatacin, bullatacinone, camptothecin, topotecan, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, KW-2189, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin γ1, dynemicin A, clodronate, esperamicin, neocarzinostatin chromophore, aclacinomycin, actinomycin, anthramycin, azaserine, bleomycin, carubicin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, methotrexate, denopterin, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatrexate, demecolcine, diaziquone, elfornithine, elliptinium acetate, epothilone, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, nitracrine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, rhizoxin, sizofuran, spirogermanium, tenuazonic acid, triaziquone, 2,2,′,2″-trichlorotriethylamine, T-2 toxin, roridin A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, paclitaxel, docetaxel, gemcitabine, 6-thioguanine, cisplatin, carboplatin, vinblastine, etoposide, vincristine, vinorelbine, novantrone, teniposide, daunomycin, aminopterin, capecitabine, ibandronate, CPT-11, difluoromethylornithine, retinoic acid, tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, LY117018, onapristone, toremifene citrate, megestrol acetate, exemestane, formestane, fadrozole, vorozole, letrozole, anastrozole, flutamide, nilutamide, bicalutamide, leuprolide, goserelin, troxacitabine, and bevacizumab; or a pharmaceutically acceptable salt thereof.

8.

Assignees

• Genentech Inc

Inventors

• Kolesnikov Aleksandr
• Do Steven

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• C07D498/16

  Peri-condensed systems · CPC title